74
Mostly True
North America
Ccr2 is labeled as a theranostic biomarker for abdominal aortic aneurysms.
The claim that Ccr2 is a theranostic biomarker for abdominal aortic aneurysms is supported by evidence indicating that CCR2 plays a role in predicting aneurysm rupture and serves as a target for therapy in animal models. Evidence from academic sources shows that CCR2 inhibition can reduce aneurysm formation and progression, and CCR2 imaging has been used in patients. Given the support from scientific literature, the claim is considered mostly true with high confidence.
Individual Claims
74
Mostly True
medical
Ccr2 is a theranostic biomarker for abdominal aortic aneurysms.
The claim is supported by scientific evidence indicating that Ccr2 is involved in the pathogenesis and theranostic applications related to abdominal aortic aneurysms. Multiple academic sources support its role in predicting rupture risk and as a therapeutic target. While direct consensus from a professional fact-check is not available, web sources provide strong support.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
80
Web Consensus Weight
50
Source Quality Score
75
Source Quality Weight
25
Llm Reasoning Score
60
Llm Reasoning Weight
25
Weighted Total
74
Evidence Summary
2 web sources corroborate, no direct fact-check found.
